Abstract Human serum heme-albumin (HSA-heme) displays globin-like properties. Here, the allosteric inhibition of ferric heme [heme-Fe(III)] binding to human serum albumin (HSA) and of ferric HSA-heme [HSA-heme-Fe(III)]-mediated peroxynitrite isomerization by isoniazid and rifampicin is reported. Moreover, the allosteric inhibition of isoniazid and rifampicin binding to HSA by heme-Fe(III) has been investigated. Data were obtained at pH 7.2 and 20.0°C. The affinity of isoniazid and rifampicin for HSA [K 0 = (3.9 ± 0.4) 9 10 In the absence and presence of CO 2 , the values of the second-order rate constant (l on ) for peroxynitrite isomerization by HSA-heme-Fe(III) are 4.1 9 10 5 and 4.3 9 10 5 M -1 s -1 , respectively. Moreover, isoniazid and rifampicin inhibit dose-dependently peroxynitrite isomerization by HSA-heme-Fe(III) in the absence and presence of CO 2 . Accordingly, isoniazid and rifampicin impair in a dose-dependent fashion the HSA-heme-Fe(III)-based protection of free L-tyrosine against peroxynitritemediated nitration. This behavior has been ascribed to the pivotal role of Tyr150, a residue that either provides a polar environment in Sudlow's site I (i.e., the binding pocket of isoniazid and rifampicin) or protrudes into the heme-Fe(III) cleft, depending on ligand binding to Sudlow's site I or to the FA1 pocket, respectively. These results highlight the role of drugs in modulating heme-Fe(III) binding to HSA and HSA-heme-Fe(III) reactivity.
In the absence and presence of CO 2 , the values of the second-order rate constant (l on ) for peroxynitrite isomerization by HSA-heme-Fe(III) are 4.1 9 10 5 and 4.3 9 10 5 M -1 s -1 , respectively. Moreover, isoniazid and rifampicin inhibit dose-dependently peroxynitrite isomerization by HSA-heme-Fe(III) in the absence and presence of CO 2 . Accordingly, isoniazid and rifampicin impair in a dose-dependent fashion the HSA-heme-Fe(III)-based protection of free L-tyrosine against peroxynitritemediated nitration. This behavior has been ascribed to the pivotal role of Tyr150, a residue that either provides a polar environment in Sudlow's site I (i.e., the binding pocket of isoniazid and rifampicin) or protrudes into the heme-Fe(III) cleft, depending on ligand binding to Sudlow's site I or to the FA1 pocket, respectively. These results highlight the role of drugs in modulating heme-Fe(III) binding to HSA and HSA-heme-Fe(III) reactivity.
Introduction
Human serum albumin (HSA) is the most abundant protein in plasma and provides a depot and carrier for many compounds. As a consequence, HSA affects the pharmacokinetics of many drugs, holds some ligands in a strained orientation that results in their metabolic modification, and renders potential toxins harmless, transporting them to disposal sites. Moreover, HSA accounts for most of the antioxidant capacity of human serum and displays enzymatic properties [1] [2] [3] [4] [5] [6] [7] [8] [9] .
HSA is a single nonglycosylated all-a-chain protein, constituted by 585 amino acids, containing three homologous domains (labeled I, II, and III). Each domain is made up of two separate subdomains (named A and B) connected by random coils. Interdomain helical regions link subdomain IB to subdomain IIA and subdomain IIB to subdomain IIIA ( Fig. 1 ) (see [2, [8] [9] [10] [11] ).
The structural organization of HSA provides several ligand binding sites (Fig. 1) . HSA displays seven binding clefts hosting chemically diverse ligands including fatty acids (FAs), and are therefore labeled FA1-FA7 (Fig. 1) . In particular, FA1 is located within the IB subdomain contacting the IB-IIA polypeptide linker and the long IB-IIA transdomain helix; FA2 is located at the interface between subdomains IA, IB, and IIA; FA3 and FA4 together contribute to Sudlow's site II (i.e., the ibuprofen primary site) in subdomain IIIA; FA5 is located within subdomains IIIA and IIIB; FA6 is a solvent-accessible linear slot located at the interface between subdomains IIA and IIB; and FA7 corresponds to Sudlow's site I (i.e., the warfarin binding site) in subdomain IIA. FA2 and FA6 clefts appear to be the secondary binding sites of ibuprofen. Moreover, HSA binds ligands (e.g., thyroxine) in the cleft between domains I and III and the bacterial HSA-binding modules to domain II [7, 9, 10, [12] [13] [14] [15] [16] [17] [18] [19] .
The FA1 binding site has evolved to selectively bind the ferric heme [heme-Fe(III)] with a high affinity (H 0 = 1.3 9 10 -8 M), so HSA participates physiologically to heme scavenging [20] [21] [22] [23] . The tetrapyrrole ring is arranged in a D-shaped cavity limited by Tyr138 and Tyr161 residues that provide p-p stacking interaction with the porphyrin and supply a donor oxygen (from Tyr161) for the heme atom. The heme is secured to HSA by the long IA-IB connecting loop that fits into the cleft opening [9, [24] [25] [26] . In turn, heme endows HSA with reactivity and spectroscopic properties similar to those of hemoglobin and myoglobin [9, 12, [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . Remarkably, both hemeFe(III) binding to HSA and human serum heme-albumin (HSA-heme) reactivity are modulated allosterically [8, 9, 19, 24, 29, 32-34, 38, 39, 42, 43] .
Here, the effect of isoniazid and rifampicin, two widely used antituberculosis drugs [44] , on heme-Fe(III) binding to HSA and ferric HSA-heme [HSA-heme-Fe(III)]-mediated peroxynitrite 1 isomerization is reported. Isoniazid and rifampicin impair heme-Fe(III) binding to HSA and vice versa, according to linked functions [45] . Moreover, isoniazid and rifampicin inhibit dose-dependently peroxynitrite isomerization by HSA-heme-Fe(III), and the HSAheme-Fe(III)-based protection of free L-tyrosine against Fig. 1 Three-dimensional structure of human serum albumin (HSA). Subdomains are labeled as follows: blue IA, cyan IB, purple IIA, green IIB, yellow IIIA, and red IIIB. Ligand binding clefts are shown and labeled FA1-FA7; FA1 is occupied by the heme (red sticks), whereas FA2-FA7 are occupied by myristate ions (black sticks). The spectroscopically active Trp214 residue (W214) is rendered in orange sticks and labeled. FA7 corresponds to Sudlow's site I (i.e., the warfarin site). The FA3 and FA4 sites form Sudlow's site II (i.e., the ibuprofen site). Atomic coordinates were taken from Protein Data Bank code 1O9X [78] . For further details, see the text peroxynitrite-mediated nitration. These results highlight the role of drugs in modulating both heme binding to HSA and HSA-heme reactivity.
Materials and methods

Materials
Hemin [iron(III) protoporphyrin IX] chloride was purchased from Sigma-Aldrich (St. Louis, MO, USA). The hemeFe(III) stock solution (5.0 9 10 -3 M) was prepared by dissolving heme-Fe(III) in 1.0 9 10 -2 M NaOH [46] . The heme-Fe(III) concentration was determined spectrophotometrically at 535 nm after converting heme-Fe(III) to the heme-Fe(III) bisimidazolate derivative in sodium dodecyl sulfate micelles (e 535 nm = 14.5 9 10 3 M -1 cm -1 ) [47] . HSA (purity 96% or better, essentially FA free) was obtained from Sigma-Aldrich. The HSA concentration was determined spectrophotometrically at 280 nm (e 280 nm = 3.82 9 10 4 M -1 cm -1 ) [46] . The HSA stock solution (2.0 9 10 -4 M) was prepared by diluting the hydrophobic ligand-free HSA solution with 2.0 9 10 -2 M sodium phosphate buffer, at pH 7.2 and 20.0°C. The HSA-hemeFe(III) stock solution (2.0 9 10 -4 M) was prepared by adding a 0.8 M defect of the heme-Fe(III) stock solution to the HSA solution (pH 7.2, 1.0 9 10 -1 M sodium phosphate buffer) at 20.0°C [33-36, 39-41, 46, 48] . The final HSA and HSA-heme-Fe(III) concentrations ranged between 1.0 9 10 -8 and 5.0 9 10 -6 M. Isoniazid and rifampicin (Fig. S1 ) were purchased from Sigma-Aldrich. The isoniazid stock solution (2.0 9 10 -1 M) was prepared by dissolving the drug in 95% water-5.0% methanol (v/v). The rifampicin stock solution (2.0 9 10 -2 M) was prepared by dissolving the drug in methanol [49] . The final isoniazid and rifampicin concentrations ranged between 1.0 9 10 -5 and 2.0 9 10 -2 M and between 1.0 9 10 -6 and 2.0 9 10 -3 M, respectively. Peroxynitrite was synthesized from KO 2 and NO and from HNO 2 and H 2 O 2 and was stored in small aliquots at -80.0°C [50, 51] . The peroxynitrite stock solution (2.0 9 10 -3 M) was diluted immediately before use with degassed 5.0 9 10 -2 M NaOH to reach the desired concentration [33, 48, [52] [53] [54] [55] . Nitrate and nitrite contaminations were in the ranges 0-7% and 8-19% of the peroxynitrite concentration, respectively (see ''Methods''). The concentration of peroxynitrite was determined spectrophotometrically prior to each experiment by measuring the absorbance at 302 nm (e 302 nm = 1.705 9 10 3 M -1 cm -1
) [50, 51, 55, 56] . Experiments in the presence of CO 2 were carried out by adding to the protein solutions the required amount of a 5.0 9 10 -1 M NaHCO 3 solution. After the addition of bicarbonate, the protein solutions were allowed to equilibrate for at least 5 min [33, 48, [52] [53] [54] [55] . For the experiments carried out in the absence of CO 2 , all solutions were thoroughly degassed and kept under nitrogen or helium [33, 48, [52] [53] [54] [55] .
All the other chemicals were obtained from SigmaAldrich and Merck (Darmstadt, Germany). All products were of analytical or reagent grade and were used without further purification.
Methods
Isoniazid and rifampicin binding to HSA
Values of the dissociation equilibrium constant for isoniazid and rifampicin binding to HSA (i.e., K 0 ) were obtained spectrofluorimetrically at pH 7.2 (1.0 9 10 -1 M phosphate buffer) and 20.0°C. The intrinsic tryptophan fluorescence of HSA in the absence and presence of isoniazid and rifampicin was recorded between 290 and 700 nm; the excitation wavelength was 280 nm. The excitation and emission slit widths were 5 nm. Small aliquots of either isoniazid (2.0 9 10 -1 M) or rifampicin (2.0 9 10 -2 M) stock solutions were added to the HSA (5.0 9 10 -6 M) solution, and the drug-dependent changes of the intrinsic fluorescence of HSA were recorded after incubation for 10 min after each addition. The intrinsic fluorescence of both drugs was recorded between 290 and 700 nm (the excitation wavelength was 280 nm) to evaluate the interference with the intrinsic tryptophan fluorescence of HSA [6, 21, 22, 57, 58] . No intrinsic fluorescence of isoniazid and rifampicin between 290 and 700 nm (the excitation wavelength was 280 nm) was observed. Test measurements performed after 2 h of HSA-drug incubation excluded slow kinetic effects.
Isoniazid and rifampicin binding to HSA was analyzed by plotting the molar fraction of the drug-HSA complex (i.e., Y) as a function of the free drug concentration. Data were analyzed according to Eq. 1 [6, 21, 22, 57, 58] :
where DF is the fluorescence change at a given drug concentration, and DF max is the fluorescence change at the saturating drug concentration. 
where DA is the absorbance change at a given drug concentration, and DA max is the absorbance change at the saturating drug concentration. -4 M) stock solution were added to the heme-Fe(III) (5.0 9 10 -7 M) solution in the absence and presence of isoniazid (3.0 9 10 -5 -3.0 9 10 -2 M) and rifampicin (3.0 9 10 -6 -3.0 9 10 -3 M). The heme-Fe(III)-dependent absorbance changes accompanying HSA-heme-Fe(III) formation were recorded after incubation for 10 min after each addition [21, 22] . Test measurements performed after 2 h of HSA-hemeFe(III) and HSA-heme-Fe(III)-drug incubation excluded slow kinetic effects.
Heme-Fe(III) binding to HSA in the absence and presence of isoniazid and rifampicin was analyzed by plotting the molar fraction of HSA-heme-Fe(III) (i.e., Y) as a function of the HSA concentration. Data were analyzed according to Eq. 3 [21, 22] :
where H corresponds to either
The dependence of the dissociation equilibrium constant H for heme-Fe(III) binding to HSA as a function of the isoniazid or rifampicin concentration was analyzed according to Eq. 4 [21, 22, 45] :
Peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III), CO 2 , isoniazid, and rifampicin
The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III), CO 2 , isoniazid, and rifampicin was recorded with SMF-20 and SMF-400 rapidmixing stopped-flow apparatus (Bio-Logic, Claix, France). The light path of the observation cuvette was 10 mm, and the dead time was 1.4 ms. The kinetics was monitored at 302 nm, the characteristic absorbance maximum of peroxynitrite (e 302 nm = 1. The kinetics of peroxynitrite isomerization by HSAheme-Fe(III) in the absence and presence of CO 2 , isoniazid, and rifampicin was analyzed in the framework of the minimum reaction mechanism (Scheme 1) [33, 53, 59] .
Values of the pseudo-first-order rate constant for HSAheme-Fe(III)-mediated peroxynitrite isomerization (i.e., l obs ) were determined in the absence and presence of CO 2 , isoniazid, and rifampicin, at pH 7.2 and 20.0°C, from the analysis of the time-dependent absorbance decrease at 302 nm, according to Eq. 5 [33, 53, 59] :
Values of the second-order rate constant for HSA-hemeFe(III)-mediated peroxynitrite isomerization (i.e., l on ) and of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (i.e., l 0 ) were determined in the absence and presence of CO 2 , isoniazid, and rifampicin, at pH 7.2 and 20.0°C, from the linear dependence of l obs on the HSA-heme-Fe(III) concentration according to Eq. 6 [33, 53, 59, 60] :
Values of l 0 for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) were also determined in the Scheme 1 Minimum reaction mechanism for peroxynitrite isomerization by HSA-hemeFe(III) absence and presence of CO 2 , isoniazid, and rifampicin, at pH 7.2 and 20.0°C, from the analysis of the timedependent absorbance decrease at 302 nm, according to Eq. 7 [33, 53, 59] :
Values of K h were determined, at pH 7.2 and 20.0°C, from the dependence of l on on the drug concentration (i.e., isoniazid concentration ranging between 2.0 9 10 -4 and 1.0 9 10 -2 M, and rifampicin concentration ranging between 4.0 9 10 -5 and 5.0 9 10 -4 M). The effect of the drug concentration on l on was analyzed according to Eq. 8 [33, 53, 59, 60] :
where l on(top) represents the value of l on under conditions where [drug] = 0 (i.e., l on(top) = l on ).
Determination of NO 2 -and NO 3 -concentration NO 2 -and NO 3 -analysis was carried out spectrophotometrically at 543 nm by using the Griess reagent and VCl 3 to catalyze the conversion of NO 3 -to NO 2 -, as described previously [33, 59, 61, 62] . Calibration curves were obtained by measuring four to eight standard sodium nitrite and sodium nitrate solutions in 1. The amount of nitro-L-tyrosine was determined by high-performance liquid chromatography, as previously reported [33] .
Values of K h were determined from the dependence on the drug concentration of the relative yield of nitro-Ltyrosine formed from the reaction of peroxynitrite with free L-tyrosine in the absence and presence of HSA-hemeFe(III), i.e., Y = [yield with added HSA-heme-Fe(III)/ yield with no HSA-heme-Fe(III)] 9 100 [33] . The effect of the isoniazid and rifampicin concentration on Y was analyzed according to Eq. 9 [33] :
where R corresponds to Y in the absence of the drug.
Data analysis
Kinetic and thermodynamic data were analyzed using the MATLAB program (The MathWorks, Natick, MA, USA). The results are given as mean values of at least four experiments plus or minus the corresponding standard deviation.
Docking analysis
Simulated automatic flexible ligand docking to HSA was performed by using Autodock 4.0 and the graphical user interface AutoDockTools [63] [64] [65] . The structure of HSAwarfarin was downloaded from the Protein Data Bank (code 2BXD) [7] . The isoniazid structure bound to cytosolic soybean ascorbate peroxidase was downloaded from the Protein Data Bank (code 2VCF) [66] . The rifampicin geometry in complex with Thermus aquaticus core RNA polymerase was downloaded from the Protein Data Bank (code 1I6V) [67] . Single bonds were allowed to rotate freely during the Monte Carlo simulated annealing procedure. The analysis of the conformational space was restricted to a cubic box of 60 Å edge centered on the coordinates of warfarin. Monte Carlo simulated annealing was performed by starting from a temperature of 900 K with a relative cooling factor of 0.95 per cycle to reach the temperature of 5 K in 100 cycles [63] [64] [65] .
Results
Isoniazid and rifampicin binding to HSA
Isoniazid and rifampicin binding to HSA was investigated by analyzing the perturbation of the intrinsic tryptophan fluorescence of HSA that arises from the unique tryptophan residue located near Sudlow's site I in subdomain IIA, at position 214 (Fig. 1) . Isoniazid induces a perturbation of the intrinsic tryptophan fluorescence of HSA similar to that induced by rifampicin [58] (data not shown), as already reported for the binding of several drugs, including warfarin, to Sudlow's site I [2, 6, 8, 9, 21, 22, 57, 68, 69] .
Therefore, the perturbation of the tryptophan fluorescence of HSA appears to be essentially drug-independent [2, 6, 8, 9, 21, 22, 57, 68] . Figure 2 shows the binding isotherms for isoniazid and rifampicin association to HSA at pH 7.2 and 20.0°C. The analysis of the data given in Fig. 2, according 
Isoniazid and rifampicin binding to HSA-heme-Fe(III)
Isoniazid and rifampicin binding to HSA-heme-Fe(III) was investigated by analyzing the perturbation of the electronic absorption spectra of HSA-heme-Fe(III). Note that Sudlow's site I and the heme cleft (Fig. 1) are spectroscopically and structurally linked [8, 9, 21, 22, 34] . Isoniazid and rifampicin induce a very similar decrease in the absorption coefficient and a superimposable blueshift of the maximum of the electronic absorption spectrum of HSA-heme-Fe(III) (data not shown), as already reported for drug binding to Sudlow's site I (e.g., warfarin). Therefore, the perturbation of the electronic absorption spectra of HSA-heme-Fe(III) appears to be essentially drug-independent [8, 9, 21, 22, 34, 69] . Figure 2 shows the binding isotherms for isoniazid and rifampicin association to HSA-heme-Fe(III) at pH 7.2 and 20.0°C. The analysis of the data given in Fig. 2, according The Hill coefficient (n) for isoniazid and rifampicin binding to HSA-heme-Fe(III) is 1.00 ± 0.03, indicating that drug binding to HSA-heme-Fe(III) is a noncooperative event.
As already reported for the association of several drugs to Sudlow's site I, heme-Fe(III) inhibits isoniazid and rifampicin binding to HSA, K 0 being lower than K h by about 1 order of magnitude (Fig. 2) . Notably, this phenomenon is essentially drug-independent [8, 9, 21, 22, 26, 34, 38, 69] .
Heme-Fe(III) binding to HSA and HSA-drug complexes Heme-Fe(III) binding to HSA in the absence and presence of isoniazid and rifampicin was investigated by analyzing the perturbation of the electronic absorption spectrum of heme-Fe(III). The absorption coefficient and the maximum of the electronic absorption spectra of HSA-heme-Fe(III)-isoniazid and HSA-heme-Fe(III)-rifampicin complexes are lower and blueshifted with respect to those of the drug-free HSA-heme-Fe(III). Furthermore, the electronic absorption spectra of HSA-heme-Fe(III)-drug complexes appear to be drug-independent [8, 9, 21, 22, 34] . Figure 2 shows the binding isotherms for heme-Fe(III) association to HSA in the absence and presence of isoniazid and rifampicin at pH 7.2 and 20.0°C. The analysis of data given in Fig. 2, according (Fig. 2) . The values of H d for heme-Fe(III) binding to HSA in the presence of saturating levels of isoniazid and rifampicin [H d = (2.1 ± 0.2) 9 10 -7 M; present study], as well as of several drugs all binding to Sudlow's site I (e.g., warfarin), appear to be essentially drug-independent [8, 9, 21, 22, 26, 34, 38, 69] . Both in the absence and in the presence of isoniazid and rifampicin, the Hill coefficient (n) for heme-Fe(III) binding to HSA is 1.00 ± 0.03, indicating that drug binding to HSA-heme-Fe(III) is a noncooperative event.
According to linked functions [45] , the values of H d , K 0 , and K h obtained experimentally (Fig. 2) are in excellent agreement with those calculated according to Eq. 4 (Fig. 2) , thus giving confidence that the assumptions underlying Eq. 4 are correct.
Effect of isoniazid and rifampicin on HSA-heme-Fe(III)-mediated peroxynitrite isomerization
The kinetics of peroxynitrite isomerization in the absence and presence of HSA-heme-Fe(III), CO 2 , isoniazid, and rifampicin was recorded by single-wavelength stoppedflow apparatus. Under all the experimental conditions, a decrease of the absorbance at 302 nm was observed, as previously reported [33] . The kinetics of peroxynitrite isomerization was fitted to a single-exponential decay for more than 95% of its course (see Eq. 5). According to the literature [33] , this indicates that no intermediate species [e.g., HSA-heme-Fe(III)-OONO; see Scheme 1] accumulate(s) in the course of peroxynitrite isomerization. In particular, the formation of the transient HSA-hemeFe(III)-OONO species represents the rate-limiting step in catalysis, the conversion of the HSA-heme-Fe(III)-OONO complex to HSA-heme-Fe(III) and NO 3 -being faster by at least 1 order of magnitude.
In the absence and presence of CO 2 , isoniazid, and rifampicin, the observed rate constants for HSA-hemeFe(III)-catalyzed isomerization of peroxynitrite (i.e., l obs ) increase linearly with the HSA-heme-Fe(III) concentration (Fig. S2) . The analysis of the data reported in Fig. 3 , according to Eq. 6, allowed the determination of the values of the second-order rate constant for peroxynitrite isomerization by HSA-heme-Fe(III) (i.e., l on , corresponding to the slope of the linear plots) and of the first-order rate constant for peroxynitrite isomerization in the absence of HSA-heme-Fe(III) (i.e., l 0 , corresponding to the y intercept of the linear plots). The values of l 0 obtained according to Eq. 6 are in excellent agreement with those experimentally determined according to Eq. 7 (see Table 1 ). In the absence of the drugs, the values of l on and l 0 for peroxynitrite isomerization in the absence and presence of CO 2 are in excellent agreement with those reported in the literature [33] .
The values of l on for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite are essentially unaffected by CO 2 (Fig. 3, Table 1 ). In contrast, the value of l 0 for peroxynitrite isomerization obtained in the presence of CO 2 (15.9 s -1 ) is higher by about 2 orders of magnitude than that obtained in the absence of CO 2 (2.8 9 10 -1 s -1 ) ( Table 1 ). The lack of a CO 2 -linked effect on peroxynitrite isomerization by HSA-heme-Fe(III) is likely related to the fact that peroxynitrite reacts faster with HSA-heme-Fe(III) (l on = 4.1 9 10 5 and I on = 4.3 9 10 5 M -1 s -1 in the absence and presence of CO 2 , respectively; Table 1 ) than with CO 2 (l on = 3 9 10 4 M -1 s -1 ) [55, 56, 70, 71] . In the absence and presence of CO 2 , isoniazid and rifampicin affect dose-dependently the l on values for HSAheme-Fe(III)-mediated isomerization of peroxynitrite (Fig. 3) . Indeed, the values of l on for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite decrease from 4. (Fig. 3 , Table 1 ). By contrast, the values of l 0 are unaffected by isoniazid and rifampicin, being only dependent on CO 2 (Fig. 3, Table 1 ).
According to Eq. 8 (Fig. 3) , the analysis of the dependence of l on for HSA-heme-Fe(III)-catalyzed isomerization of peroxynitrite on the isoniazid and rifampicin concentrations allowed the determination of the CO 2 -independent values of K h for isoniazid and rifampicin binding to HSA-heme-Fe(III) [(4.3 ± 0.4) 9 10 -3 and (1.2 ± 0.1) 9 10 -4 M, respectively]. The Hill coefficient (n) for isoniazid and rifampicin binding to HSA-heme-Fe(III) is 1.00 ± 0.02, indicating that drug binding to HSA-hemeFe(III) is a noncooperative event.
Under conditions where the drug concentration is much greater than K h , HSA-heme-Fe(III) does not catalyze the isomerization of peroxynitrite as observed in the presence of noncatalytic HSA and HSA-heme-Fe(III)-cyanide [33] .
Analysis of the nitrogen-containing products of HSA-heme-Fe(III)-mediated peroxynitrite isomerization
According to the literature [33, 53, 59] , the spontaneous isomerization of peroxynitrite yields 74 ± 5% NO 3 -and 24 ± 4% NO 2 -. In the presence of HSA-heme-Fe(III), the NO 3 -and NO 2 -yields increase (approximately 90%) and decrease (approximately 10%), respectively. The same result has been observed in the presence of HSA-hemeFe(III) and CO 2 . Lastly, isoniazid and rifampicin do not significantly affect the NO 3 -and NO 2 -yields (Table 2 ).
Isoniazid and rifampicin inhibit HSA-heme-Fe(III)-based protection of free L-tyrosine against peroxynitrite-mediated nitration HSA-heme-Fe(III) protects dose-dependently free L-tyrosine against peroxynitrite-mediated nitration [33] . As shown in Fig. 4 , isoniazid and rifampicin inhibit in a dosedependent fashion the HSA-heme-Fe(III)-based protection of free L-tyrosine against peroxynitrite-mediated nitration in the absence and presence of CO 2 . In fact, the relative yield of nitro-L-tyrosine increases on increasing the isoniazid and rifampicin concentrations at fixed HSA-hemeFe(III), peroxynitrite, L-tyrosine, and CO 2 concentrations. According to Eq. 9 (Figs. 4, S3) , the analysis of the dependence on the isoniazid and rifampicin concentrations of the relative yield of nitro-L-tyrosine formed from the reaction of peroxynitrite with free L-tyrosine (Y) allowed the determination of the CO 2 -independent values of K h for isoniazid and rifampicin binding to HSA-heme-Fe(III) [(3.6 ± 0.4) 9 10 -3 and (1.7 ± 0.2) 9 10 -4 M, respectively, at 20.0°C; and (4.3 ± 0.4) 9 10 -3 and (2.1 ± 0.2) 9 10 -4 M, respectively, at 37.0°C]. Under all the experimental conditions, the Hill coefficient (n) for isoniazid and rifampicin binding to HSA-heme-Fe(III) ranges between 0.98 ± 0.02 and 1.01 ± 0.02, indicating that drug binding to HSA-hemeFe(III) is a noncooperative event. Note that the data obtained at 20.0°C agree with those determined at 37.0°C (see Figs. 4,  S3) . Under conditions where the drug concentration is much greater than K h , HSA-heme-Fe(III) does not protect free L-tyrosine against peroxynitrite-mediated nitration.
As expected, the values of K h obtained spectrophotometrically (Fig. 2) and from the dependence of l on on the isoniazid and rifampicin concentrations (Fig. 3) are in excellent agreement with those obtained from the dependence of the relative yield of nitro-L-tyrosine formed from the reaction of peroxynitrite with free L-tyrosine on the drug concentration (Figs. 4, S3) . An automated docking analysis of isoniazid and rifampicin was performed in Sudlow's site I (FA7) of HSA to confirm that these drugs could easily bind to this site (Fig. 5) .
Isoniazid, a small ligand, binds to the FA7 subchamber, where the coumarinic ring of warfarin is located, with an interaction energy of -24.3 kJ mol -1 , in agreement with that calculated from K 0 . On the other hand, rifampicin only partially enters into Sudlow's site I opening that recognizes the benzyl group of warfarin. Therefore, this prevents the determination of the rifampicin docking energy. It should be noticed, however, that the simulation does not take into account induced-fit conformational changes involving the protein backbone [64] .
Discussion
Isoniazid and rifampicin bind noncooperatively to Sudlow's site I, as suggested by the drug-dependent quenching of the intrinsic HSA fluorescence [6, 21, 22, 57, 58, 69] . As expected for Sudlow's site I ligands, both antituberculosis drugs modulate allosterically heme-Fe(III) binding to HSA as well as peroxynitrite isomerization by HSA-hemeFe(III), highlighting the role of heterotropic ligands in modulating the HSA(-heme) reactivity [8, 32, 48, 72] . The affinity of isoniazid and rifampicin for HSA decreases by about 1 order of magnitude in the presence of saturating amounts of heme-Fe(III) (Fig. 2) . Further, as expected on the basis of linked functions [45] , the hemeFe(III) affinity for HSA decreases by about 1 order of magnitude in the presence of saturating amounts of isoniazid and rifampicin (Fig. 2) . Accordingly, the difference in the reaction free energy for drug binding to HSA in the absence and presence of heme-Fe(III) [dDG°= -RT ln(K 0 /K h ) = 5.6 ± 0.2 kJ mol -1 ] is similar to the difference in the reaction free energy for heme-Fe(III) binding to HSA in the absence and presence of drugs [dDG°= -RT ln(H 0 /H d ) = 5.8 kJ mol
-1 ] at pH 7.2 and 20.0°C. This value, which is essentially drug-independent [8, 9, 21, 22, 26, 34, 38, 69] , indicates that the interaction energy between the Sudlow's site I and FA1, where the heme binds, is 5.7 kJ mol -1 independent of the affinity of the drug for Sudlow's site I; this value likely reflects the free energy associated with the conformational change(s) required for the structural communication between the two sites.
Peroxynitrite isomerization is facilitated by HSA-hemeFe(III) (see the present study and [33] ). However, unlike ibuprofen inhibition of HSA-heme-Fe(III) action by binding to Sudlow's site II [33] , isoniazid and rifampicin impair allosterically HSA-heme-Fe(III)-mediated peroxynitrite isomerization by binding to Sudlow's site I (Fig. 5) . This behavior could reflect drug-dependent structural changes occurring at the heme binding pocket of HSA. Indeed, abacavir binding to Sudlow's site I modulates peroxynitrite-mediated oxidation of ferrous nitrosylated HSA-heme [HSA-heme-Fe(II)-NO] [48] . Moreover, abacavir binding and warfarin binding to Sudlow's site I facilitate HSAheme-Fe(II)-NO denitrosylation [31] . Both events reflect the drug-dependent neutral-to-basic conformational transition in HSA-heme-Fe(II)-NO [31, 48] . Sudlow's site I ligands interact with Tyr150 and Arg252 residues, two key residues positioned in the center of the drug binding site. In turn, Tyr150 drives the reorientation of Phe149, which is no longer available for the stabilization of the heme-Fe(III) porphyrin ring by p-p stacking, with a consequent effect on the heme-Fe(III)-based catalysis (see the present study and [9, 31, 33, 48] ).
Peroxynitrite isomerization by heme-Fe(III) proteins [e.g., HSA-heme-Fe(III)] could represent a physiological detoxification mechanism, protecting cells from reactive nitrogen and oxygen species [70, 71] ; this potential role is reinforced by the evidence that enzymatically active HSAheme-Fe(III) indeed protects L-tyrosine from the nitrosylation (see Figs. 4, S3) . Note that the rate of peroxynitrite isomerization by HSA-heme-Fe(III) is faster by about 1 order of magnitude than the rates reported for ferric horse heart myoglobin, sperm whale myoglobin, and human hemoglobin [33, 53, 59] . Moreover, peroxynitrite isomerization by HSA-heme-Fe(III) is faster than peroxynitrite , and 1.2 9 10 -3 M, respectively. Where not shown, the standard deviation is smaller than the symbol. For details, see the text scavenging by ferrous nitrosylated heme proteins, which appears to be strongly limited by (1) the dissociation of the heme-Fe(III)-NO transient and (2) the reduction of the final heme-Fe(III) species to the ferrous heme derivative [33, 48] .
Owing to the role of HSA in human plasma [1] [2] [3] [4] [5] [6] [7] [8] [9] , some in vivo implications could be argued from the present results:
1. Peroxynitrite isomerization by HSA-heme-Fe(III) could occur only in patients affected by diseases where a relevant intravascular hemolysis takes place. Under these pathological conditions, the HSA-heme-Fe(III) plasma level increases from the physiological concentration (approximately 1 9 10 -6 M) to approximately 4 9 10 -5 M [20, 73] . To mimic as much as possible this condition, the HSA-heme-Fe(III) concentration here used ranged from 5.0 9 10 -6 to 5.0 9 10 -5 M. 2. Although the in vivo concentration of peroxynitrite is openly debated, the level of peroxynitrite in the reperfused ischemic heart has been reported to be much higher than micromolar concentration, at least over a brief period of time [70, 71] , overlapping the lowest peroxynitrite concentration here used (2.5 9 10 -5 M). 3. Accounting for the plasma HSA concentration (approximately 7.5 9 10 -4 M) [2] , the plasma levels of isoniazid and rifampicin (ranging between 1 9 10 -5 and 1 9 10 -4 M [74, 75] ), and the values of K 0 and K h determined here, the molar fraction of the drug-bound HSA and HSA-heme-Fe(III) could range between 10 and 50%.
Any inhibitory effect on peroxynitrite isomerization by HSA-heme-Fe(III) results in a relevant effect on the putative HSA detoxification role. The fact that several drugs binding at different sites of HSA might reduce this potentially important role should induce some caution for the simultaneous drug administration employed for several therapeutic protocols. Thus, this control should be carried out routinely to avoid some paradoxical therapeutic effect, as for the management of antituberculosis therapy. Indeed, the increase of the plasma levels of heme-Fe(III) under pathological conditions [20, 72] may induce a release of antituberculosis drugs; accordingly, the toxic free-heme plasma concentration could increase in patients under antituberculosis drug therapy. Moreover, the protective role of HSA-heme-Fe(III), catalyzing peroxynitrite detoxification, could be impaired by antituberculosis drugs; this could facilitate the peroxynitrite-mediated nitration of aromatic residues (such as Tyr), which represents a relevant posttranslational protein modification process [70, 71, 76] . 
